Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases

Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With... Letters Figure. Saliva Sensitivity by Collection Timing After COVID-19 Onset Overall and in Symptomatic and Asymptomatic Individuals A All participants B Symptomatic and asymptomatic participants P <.001 Symptoms at time P <.001 of collection P <.001 P <.001 100 100 Yes No P =.005 P =.31 P =.19 P ≥.99 80 80 60 60 40 40 20 20 0 0 <7 7-13 14-20 21-27 ≥28 <7 7-13 14-20 21-27 ≥28 (n = 118) (n = 142) (n = 116) (n = 68) (n = 80) Days post–COVID-19 onset Days post–COVID-19 onset Saliva sensitivity in all 524 nasopharyngeal-positive paired samples from 256 onset, defined as the earliest of either first symptom or first reverse participants (A) and participants who were symptomatic vs asymptomatic at transcriptase–polymerase chain reaction positivity. Error bars indicate 95% CIs. time of specimen collection (B) grouped by collection timing after COVID-19 (Bender, Pannaraj); Department of Pathology and Laboratory Medicine, 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical- University of Southern California, Los Angeles (Bard). specimens.html Accepted for Publication: August 1, 2021. 2. Moreno-Contreras J, Espinoza MA, Sandoval-Jaime C, et al. Saliva sampling and its direct lysis, an excellent option to increase the number of SARS-CoV-2 Published Online: August 13, 2021. doi:10.1001/jama.2021.13967 diagnostic tests http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases

Loading next page...
 
/lp/american-medical-association/therapeutic-drug-monitoring-vs-standard-therapy-during-infliximab-aDj9qJV3c2
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.11477
Publisher site
See Article on Publisher Site

Abstract

Letters Figure. Saliva Sensitivity by Collection Timing After COVID-19 Onset Overall and in Symptomatic and Asymptomatic Individuals A All participants B Symptomatic and asymptomatic participants P <.001 Symptoms at time P <.001 of collection P <.001 P <.001 100 100 Yes No P =.005 P =.31 P =.19 P ≥.99 80 80 60 60 40 40 20 20 0 0 <7 7-13 14-20 21-27 ≥28 <7 7-13 14-20 21-27 ≥28 (n = 118) (n = 142) (n = 116) (n = 68) (n = 80) Days post–COVID-19 onset Days post–COVID-19 onset Saliva sensitivity in all 524 nasopharyngeal-positive paired samples from 256 onset, defined as the earliest of either first symptom or first reverse participants (A) and participants who were symptomatic vs asymptomatic at transcriptase–polymerase chain reaction positivity. Error bars indicate 95% CIs. time of specimen collection (B) grouped by collection timing after COVID-19 (Bender, Pannaraj); Department of Pathology and Laboratory Medicine, 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical- University of Southern California, Los Angeles (Bard). specimens.html Accepted for Publication: August 1, 2021. 2. Moreno-Contreras J, Espinoza MA, Sandoval-Jaime C, et al. Saliva sampling and its direct lysis, an excellent option to increase the number of SARS-CoV-2 Published Online: August 13, 2021. doi:10.1001/jama.2021.13967 diagnostic tests

Journal

JAMAAmerican Medical Association

Published: Sep 21, 2021

References